ReviewBMC medicine2026
Conflicting evidence for continuous glucose monitoring in gestational diabetes: current challenges and the imperative for individual participant data meta-analysis.
Review in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of gestational diabetes mellitus (GDM) is rising along with rates of obesity and type 2 diabetes. GDM is associated with an increased risk of various short- and long-term complications for both mother and child, including type 2 diabetes. Managing GDM requires a multidisciplinary approach that includes dietary guidance, promoting regular physical activity, and performing self-monitoring of blood glucose (SMBG). Continuous glucose monitoring (CGM) has transformed pregnancy care in women with type 1 diabetes and is increasingly being proposed as a strategy to improve glycaemic management in GDM. By capturing postprandial glucose excursions, glycaemic variability, and time in range, CGM provides a more detailed picture of glycaemia and has raised expectations of improved metabolic control and pregnancy outcomes. MAIN BODY: Despite these theoretical advantages, evidence for CGM in GDM remains conflicting. More recently, several large randomized controlled trials (RCT's) show conflicting data: some studies show modest improvements in glycaemic measures, whereas others report no clear benefit for key maternal or neonatal outcomes, leaving the clinical value and cost-effectiveness of CGM unclear. A major limitation is the absence of validated CGM-based glycaemic targets specific to GDM, and current guidelines offer little direction beyond conventional SMBG guidelines. Future research should prioritize adequately powered large RCT's representing a broad population, and, importantly, individual participant data meta-analyses to reconcile inconsistent findings, identify subgroups most likely to benefit, establish pregnancy-specific CGM thresholds, and evaluate the impact on both obstetric outcomes and long-term postpartum metabolic risk.
conclusionsThis ongoing debate underscores the need to critically appraise the role of CGM in GDM, summarize results from completed RCT's and meta-analyses, recognize key methodological and clinical evidence gaps, and outline the steps required for CGM to become fully integrated into standard GDM care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.